Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -51.60% is 284% below its 5-year average of -13.43%, around the middle of its 5-year range (-89.62%–27.38%).
50.01% below its 12-month average of -34.40%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-12-31): -89.62%.
EBITDA MARGIN
-51.60%
EBITDA MARGIN AVG TTM
-34.40%
EBITDA MARGIN AVG 3Y
-27.13%
EBITDA MARGIN AVG 5Y
-13.43%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-50.01%
CURRENT VS 3Y AVG
-90.23%
CURRENT VS 5Y AVG
-284.23%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Zhongchao Inc.
Market Cap
$30389.00
EBITDA Margin
-51.60%
TTM Avg
-34.40%
3Y Avg
-27.13%
5Y Avg
-13.43%
Market Cap
$29771.00
EBITDA Margin
-44.11%
TTM Avg
-77.20%
3Y Avg
-45.21%
5Y Avg
-40.80%
Market Cap
$6235.00
EBITDA Margin
-216.38%
TTM Avg
-116.97%
3Y Avg
-54.20%
5Y Avg
-40.74%
Market Cap
$61172.00
EBITDA Margin
-1762.94%
TTM Avg
-1134.94%
3Y Avg
-792.43%
5Y Avg
-12891.91%
Market Cap
$70884.00
EBITDA Margin
-24782.35%
TTM Avg
-24782.35%
3Y Avg
-17538.85%
5Y Avg
-17538.85%
Market Cap
$110112.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$250443.00
EBITDA Margin
-994.74%
TTM Avg
-759.01%
3Y Avg
-558.46%
5Y Avg
-556.54%
Market Cap
$378849.00
EBITDA Margin
-47981.26%
TTM Avg
-69951.07%
3Y Avg
-52738.28%
5Y Avg
-42190.63%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zhongchao Inc. (ZCMD) | $30389.00 | -51.60% | -34.40% | -27.13% | -13.43% |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $29771.00 | -44.11% | -77.20% | -45.21% | -40.80% |
| NewGenIvf Group Limited (NIVF)vs › | $6235.00 | -216.38% | -116.97% | -54.20% | -40.74% |
| Akanda Corp. (AKAN)vs › | $61172.00 | -1762.94% | -1134.94% | -792.43% | -12891.91% |
| PRF Technologies Ltd. (PRFX)vs › | $70884.00 | -24782.35% | -24782.35% | -17538.85% | -17538.85% |
| Psyence Biomedical Ltd. (PBM)vs › | $95475.00 | N/A | N/A | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $110112.00 | N/A | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | -994.74% | -759.01% | -558.46% | -556.54% |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | -47981.26% | -69951.07% | -52738.28% | -42190.63% |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | -2196.68% | -1727.24% | -1664.72% | -2055.32% |
Gross Margin
42.5%
EBITDA Margin
-51.6%
Operating Margin
-54.4%
Net Margin
-55.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -89.62% |
| 2025-06-30 | -12.41% |
| 2024-12-31 | -1.17% |
| 2024-06-30 | 2.11% |
| 2023-12-31 | -5.11% |
| 2023-06-30 | -38.78% |
| 2022-12-31 | -44.90% |
| 2022-06-30 | 11.71% |
| 2021-12-31 | -10.19% |
| 2021-06-30 | 13.25% |
| 2020-12-31 | 27.38% |
| 2020-06-30 | 22.22% |
| 2019-12-31 | 32.72% |
| 2019-06-30 | 18.04% |
